Limited data are available about the impact of antimicrobial resistance on clinical outcomes in cases of pneumococcal pneumonia. This was studied in 146 persons hospitalized with invasive pneumonia due to Streptococcus pneumoniae (minimum inhibitory concentration of cefotaxime, у.25 mg/mL) who were identified through population-based active surveillance for the period of November 1994 through April 1996. Compared with matched control subjects who had infection with more-susceptible S. pneumoniae, the proportion of subjects who died or who were admitted to an intensive care unit did not differ significantly. Multivariable analysis showed no significant contribution of antimicrobial resistance to mortality or the requirement for care in an intensive care unit. The ability to detect an effect of antimicrobial resistance on these important outcome measures may have been influenced by aggressive multidrug empirical therapy in this group of hospitalized patients. Factors other than resistance, such as severity of illness at presentation and advance directive status ("do not resuscitate" orders), appear to have a stronger influence on pneumococcal pneumonia outcomes.
Limited data are available about the impact of antimicrobial resistance on clinical outcomes in cases of pneumococcal pneumonia. This was studied in 146 persons hospitalized with invasive pneumonia due to Streptococcus pneumoniae (minimum inhibitory concentration of cefotaxime, у.25 mg/mL) who were identified through population-based active surveillance for the period of November 1994 through April 1996. Compared with matched control subjects who had infection with more-susceptible S. pneumoniae, the proportion of subjects who died or who were admitted to an intensive care unit did not differ significantly. Multivariable analysis showed no significant contribution of antimicrobial resistance to mortality or the requirement for care in an intensive care unit. The ability to detect an effect of antimicrobial resistance on these important outcome measures may have been influenced by aggressive multidrug empirical therapy in this group of hospitalized patients. Factors other than resistance, such as severity of illness at presentation and advance directive status ("do not resuscitate" orders), appear to have a stronger influence on pneumococcal pneumonia outcomes.
Poor outcomes in patients with community-acquired pneumonia have been linked to advanced age, the presence of coexisting disease, severe derangement of physiological and laboratory parameters, and infection caused by particular pathogens [1] [2] [3] [4] . However, the impact of antimicrobial resistance on clinical outcomes in cases of pneumococcal pneumonia has not been as well documented.
Streptococcus pneumoniae remains the leading cause of community-acquired pneumonia [5] , accounting for nearly 125,000 hospitalizations each year [6] . In the United States, the prevalence of strains that are resistant to penicillin has increased steadily during the past decade, with proportions that are nonsusceptible being 130% in some areas [7] . Studies in other countries with high rates of pneumococcal resistance have found that clinical outcomes among patients with nonmeningitic infections caused by nonsusceptible organisms are not worse than those caused by susceptible organisms [8] [9] [10] .
Several characteristics of previous studies have limited their generalizability. These include restriction of analysis to the experiences at a single institution [8, 9] , a focus on pediatric patients, who are less likely to have poor outcomes from pneumonia [8, 10] , and enrollment of relatively small numbers of patients who are infected with agents that are fully resistant to penicillin or cephalosporins (i.e., the majority of the nonsusceptible isolates had intermediate susceptibility to penicillin or cephalosporin).
A recent report based on surveillance data from the United States found excess mortality due to pneumonia among patients infected with highly resistant pneumococci [6] . However, important determinants of clinical outcome, such as therapy and severity of illness at presentation, could not be considered in that analysis. We report results of a study of outcomes of community-acquired invasive pneumococcal pneumonia that considers these additional determinants of outcome. The study used population-based active surveillance for invasive disease in 3 geographic areas in the United States and evaluated clinical outcomes during the period of 1994-1996.
METHODS

Surveillance for Invasive Pneumococcal Infection
Laboratory-based surveillance for invasive disease due to S. pneumoniae was conducted in 3 metropolitan areas: Atlanta (Clayton, Cobb, DeKalb, Douglas, Fulton, Gwinnett, Newton, and Rockdale Counties), Baltimore (Baltimore City and Baltimore County), and San Antonio, Texas (Bexar County). Invasive disease was defined as isolation of the organism from a normally sterile site (e.g., blood, CSF, pleural fluid, peritoneal fluid). Surveillance personnel collected isolates from microbiology laboratories serving long-term care hospitals in the surveillance areas and completed standardized 2-page case report forms. Isolates were sent to the Centers for Disease Control and Prevention, Atlanta, or the University of Texas Health Sciences Center at San Antonio for antimicrobial susceptibility testing by use of the broth dilution method. The operational details of this surveillance system have been described elsewhere [6, [11] [12] [13] . We restricted our study of clinical outcomes to pneumonia cases that occurred in persons who were residents of and admitted to hospitals in Atlanta, Baltimore, or San Antonio from 1 November 1994 through 30 April 1996.
Study Design
Two approaches were used: a matched case-control study and a cohort study. Decreasing b-lactam susceptibility occurs in a stepwise fashion following alteration in penicillin binding proteins [14] , even among strains of S. pneumoniae classified as susceptible by the National Committee for Clinical Laboratory Standards (NCCLS). For this reason, the matched case-control study was designed to allow evaluation of a spectrum of elevated MICs and their impact on clinical outcomes. A case patient was defined as a patient with invasive disease and an S. pneumoniae isolate with a MIC of cefotaxime of у0.25 mg/mL; potential control subjects had invasive disease and isolates with a MIC of cefotaxime of р0.0625 mg/mL. Of note, the NCCLS classifies pneumococcal susceptibility to cefotaxime as follows: susceptible, MIC of р0.5 mg/mL; intermediate, MIC of 1.0 mg/ mL; and resistant, MIC of у2 mg/mL [15] . Without knowing at what point clinical outcome would be influenced by an increasing MIC, episodes of invasive disease due to organisms with elevated MICs of cefotaxime, despite the organisms' categorical classification as susceptible by NCCLS, were considered to be cases. For the case-control analysis, these cases were compared with control organisms also classified as susceptible by NCCLS, but with lower MICs of cefotaxime.
Among the 98 case patients enrolled in the case-control study, 47 (48%) had isolates classified as susceptible to cefotaxime. Among the 146 case patients enrolled in the cohort study, 61 (42%) had isolates susceptible to cefotaxime (figure 1). Because not all case patients could be matched to suitable control subjects, evaluation of the cohort permitted analysis of a greater number of case patients.
After identifying patients with invasive pneumococcal pneumonia by means of case report form designations, we attempted to identify 2 control subjects per case patient, matched by age, presence or absence of underlying condition(s) likely to cause worse clinical outcomes, and hospital. Age matching was done as follows: for case patients aged 0-3 years, control subjects were ‫1ע‬ year of age; for patients aged years, ‫2ע‬ years; for patients aged 112-18 years, ‫5ע‬ years; for patients aged 118 years, ‫01ע‬ years. Conditions classified as underlying disease likely to contribute to worse clinical outcomes in cases of pneumonia included chronic cardiovascular disease, chronic obstructive lung disease, diabetes mellitus, chronic liver disease, asplenia, AIDS (with a documented CD4 cell count of !100 cells/mL), malignancy that was not in remission, presence of a transplanted organ, and long-term use of corticosteroids or other immunosuppressive medications [1] [2] [3] [4] . Alcoholism without mention of liver disease was not considered an underlying condition, because of presumed inconsistent documentation of the condition in the medical record [16] . As previous studies have supported, HIV infection with a CD4 cell count that was unknown or у100 cells/mL was not classified as an underlying disease likely to cause worse outcomes [17] [18] [19] .
By use of the surveillance system, we identified control subjects from among patients with invasive pneumococcal pneumonia due to organisms with a MIC of cefotaxime of р0.0625 mg/mL who were admitted to the same hospital as the case patient, and we restricted enrollment to hospitals that submitted 130 isolates for testing during the study period. We conducted a retrospective review of medical records for selected persons with pneumococcal pneumonia identified from case report form data. A standardized data abstraction instrument was used to collect information on demographic characteristics, diagnosis and procedure codes, medications, underlying diseases, advance directive status (i.e., "do not resuscitate" [DNR] orders), and clinical presentation and hospital course, including vital signs, antibiotic therapy, and laboratory results.
Pneumonia was defined as illness that met у1 of the following 3 criteria: admission chest radiograph suggestive of a diagnosis of pneumonia (i.e., the words "pneumonia," "consolidation," "air space disease," or "infiltrate" used in the radiology report), S. pneumoniae cultured from pleural fluid, or an abnormal admission chest radiograph and an International Classification of Diseases, 9th revision, code for bacterial pneumonia on the medical record. We limited our analysis to community-acquired cases of invasive pneumococcal pneumonia-that is, only those for which S. pneumoniae was isolated within 48 h of admission. Persons with concurrent meningitis were excluded from this analysis and have been described elsewhere [13] .
Ages were categorized into the following groups: children (!18 years old), adults (18-75 years old), and older adults (у75 years old). Selection of these groupings is supported by the findings of a report that demonstrated that mortality rates due to pneumococcal pneumonia among persons aged 65-74 years are more like those for persons aged 18-64 years than they are like those for persons aged у75 years [6] . Previously validated scoring systems were used to adjust for severity of illness at presentation. Acute Physiology and Chronic Health Evaluation II scores were calculated for adults and older adults [20] , and pediatric risk of mortality (PRISM) scores were calculated for children [21] by use of the first of each parameter measured within the first 48 h of hospitalization. For multivariable analysis, the ranges of possible scores were classified into quartiles, with the referent quartile being that with scores representing the most normal physiology. When a particular parameter was missing, the parameter was assumed to be within the normal range.
Patient isolates were tested for susceptibility to the following antibiotics: amoxicillin, cefotaxime, chloramphenicol, clindamycin, trimethoprim-sulfamethoxazole, erythromycin, meropenem, ofloxacin, penicillin, rifampin, tetracycline, and vancomycin. In certain cases, the susceptibility of an isolate to an antibiotic not included in the test panel was inferred. Isolates susceptible to penicillin or amoxicillin were considered to be susceptible to all penicillins and to cefuroxime, isolates susceptible to ofloxacin were considered to be susceptible to all quinolones, isolates susceptible to cefotaxime were considered to be susceptible to all second-and third-generation cephalosporins, and isolates susceptible to tetracycline were also considered to be susceptible to doxycycline.
Data collected for antibiotic therapy during the first 48 h of hospitalization were used to classify the type of therapy given. Because the antimicrobial susceptibility of organisms cultured from samples collected at admission is seldom known within 48 h, antibiotic treatment choices made during this interval were assumed to be empirical. Discordant antibiotic therapy was defined as the lack of receipt of any antibiotic to which the S. pneumoniae isolate was susceptible or of intermediate susceptibility. Indeterminate therapy was defined as receipt of only antibiotics to which the isolate was, at best, of intermediate susceptibility or the susceptibility of an isolate to an antibiotic not included in the test panel could not be reasonably inferred. Concordant therapy occurred when the patient received у1 antibiotic during the first 48 h of hospitalization to which their isolate was fully susceptible. Patients whose therapy was classified as concordant because they were treated with vancomycin, which is not typically used in the empirical treatment of pneumonia [22, 23] , were evaluated separately because their illness was considered likely to be more severe.
Statistical Analysis
Statistical analysis was done with SAS software, version 6.12 (SAS Institute). A P value of р.05 was considered significant. Two main analyses were done: a matched case-control analysis (restricted to case patients with at least 1 matched control) and a cohort analysis of all subjects with isolates with elevated MICs of cefotaxime (у0.25 mg/mL).
Matched analysis of case patients and control subjects. The dependent variable in the matched analysis was MIC classification (subjects with an isolate with an MIC of cefotaxime of р0.0625 mg/mL vs. those with an isolate with an MIC of у0.25 mg/mL). Conditional logistic regression, by means of the PHREG procedure, was used to adjust for several potential confounders at once.
Cohort analysis of case patients who had isolates with MICs of cefotaxime of у0.25 mg/mL. The outcome variables considered in the cohort analysis were mortality and requirement for hospitalization in the intensive care unit (ICU) during the first 7 days of hospitalization. The Cochran-Mantel-Haenszel test was used for comparisons of proportions in the uni-2 ϫ 2 variate analysis. Poisson regression with the GENMOD procedure was used in the multivariable cohort analyses. Variables were considered for inclusion in the model on the basis of level of statistical significance in the univariate analysis and consideration of biological plausibility. The final model included severity of illness, age category, therapeutic classification, underlying disease, documentation of a DNR order on the patient's record, and MIC of cefotaxime.
RESULTS
The populations in Atlanta, Baltimore, and San Antonio under surveillance during the study period totaled ∼5.4 million persons (according to 1995 census data). There were 2510 episodes of invasive pneumococcal disease (31.0 cases per 100,000 population per year), 934 (37.2%) of which were designated as pneumonia on case report forms. The annual incidence was 11.5 episodes per 100,000 population. Of all of the invasive pneumococcal pneumonia cases identified, 778 patient isolates (83%) were available for susceptibility testing; 4.5% were classified as intermediately susceptible to cefotaxime (MIC, 1.0 mg/ mL) and 3.5% were classified as resistant (MIC, у2.0 mg/mL).
Of 187 patients with invasive pneumococcal pneumonia (exclusive of those with comorbid meningitis) and isolates with MICs of cefotaxime of у0.25 mg/mL, records were abstracted for 146 cases (78%; figures 1 and 2). The remainder of the records were not abstracted because they could not be located after at least 3 requests were made to the hospital's medical records department. Ninety-eight (67%) of the 146 case patients could be matched to 157 control subjects. Isolates from 7 (32%) of the 22 child case patients were classified as inter- mediately susceptible to cefotaxime, and those from 6 child case patients (27%) were classified as resistant. For the 88 adults, 29 (33%) had intermediately susceptible pneumococcal isolates and 21 (24%) had resistant isolates, whereas among the isolates from 36 older adults, 4 (11%) were intermediate and 18 (50%) were resistant. These differences were not statistically significant ( ). P p .18 Twenty-two patients (15%) received therapy classified as discordant. Twenty of these patients were infected with isolates that were fully resistant to cefotaxime (MIC, у2.0 mg/mL), and 2 patients had isolates of intermediate susceptibility to cefotaxime (MIC, 1.0 mg/mL) and did not receive this antimicrobial agent during the first 48 h of hospitalization.
Of these 303 patients (146 matched and unmatched case patients plus 157 control subjects), 288 (95%) were detected by the surveillance system because their blood cultures yielded S. pneumoniae, and the remainder had S. pneumoniae recovered from pleural or pericardial fluid or lung tissue. Figure 2 depicts the distribution of subjects (case patients [matched and unmatched] and control subjects), according to MIC of cefotaxime. More cases ( ) were considered to be due to susceptible organn p 61 isms than were considered to be due to intermediate ( ) n p 40 or resistant ( ) organisms, according to the NCCLS n p 45 definitions.
Matched analysis of case patients and control subjects. Characteristics of the case patients and their matched control patients are listed in table 1. Case patients did not differ significantly from control subjects with regard to mortality, proportion admitted to an ICU within the first 7 days of hospitalization, proportion with underlying disease or HIV infection, proportion that were treated empirically with vancomycin, proportion with DNR orders in the medical record, and mean length of stay ( ). Suppurative complications, such as P 1 .05 empyema or pulmonary abscess, were not more likely to occur in case patients than they were in control subjects. Control subjects were significantly more likely to have a worse severity score at presentation than were case patients ( ). When P p .02 analysis was restricted to the 26 matched sets in which the case isolate had an MIC of cefotaxime of у2.0 mg/mL, no differences were identified between case patients and control subjects, and the difference in disease severity was no longer significant (data not shown). Multivariable conditional logistic regression found no relation between case status and mortality or ICU admission in the first 7 days of hospitalization.
Cohort analysis of case patients with isolates with MICs of cefotaxime of у0.25 mg/mL. Univariate analysis was used to identify factors associated with severe outcomes among 146 case patients. Patients with DNR orders and more severe illness at presentation were significantly more likely to die (table 2) . Death was also more common among subjects with advanced age (у75 years) and underlying disease, although these associations did not reach statistical significance. Deaths were not more likely to occur among those treated with antimicrobial agents to which the pneumococcal isolate was not susceptible.
When multivariable analysis was used to compare the relative contribution of the factors associated with mortality, only the influence of DNR orders remained significant (table 3) . The association between severity of illness and mortality remained strong, however. Late deaths (deaths that occurred 148 h after admission) were evaluated to determine if antimicrobial treatment played a more significant role [6] . When case patients who died within the first 48 h of admission were excluded, multivariable analysis showed a stronger association between underlying disease and mortality. Whether considering all deaths or late deaths, the level of cefotaxime resistance did not correlate with increasing risk of mortality.
Patients whose pneumonia at presentation was associated with a higher severity score were more likely to be admitted to an ICU, whereas age, DNR orders, therapy classification, and underlying disease did not contribute significantly to whether the patient required care in the ICU (table 4) .
Multivariable analysis of the factors associated with admission to an ICU showed a continued association with severe illness, although this was not statistically significant. No other factors, including the level of cefotaxime resistance, were associated with admission to an ICU (table 5) .
Empirical treatment for invasive pneumococcal pneumonia. Therapy for pneumococcal pneumonia within the first 48 h of hospitalization among the 146 case patients usually consisted of a combination of agents. Of the 132 patients for whom complete information about empirical antibiotic therapy was available, 51 patients (38%) received only 1 antibiotic during the first 48 h, 52 (39%) received 2, 23 (17%) received 3, and 8 (6%) received у4. Cefuroxime was the agent used most commonly, followed by ceftriaxone. However, ceftriaxone was the agent most commonly used in single-drug regimens, followed by cefuroxime and cefotaxime. Erythromycin was never used as a single agent, but it was the third most commonly used drug in combination therapy (table 6) .
DISCUSSION
The choice of antimicrobial agent(s) for the empirical treatment of suspected bacterial pneumonia is guided by such factors as age, severity of the patient's illness at presentation, and other clinical and historical factors [22, 23] . Most patients with pneumonia are treated without being hospitalized [24] , and 20% of persons hospitalized with pneumonia attributed to S. pneumoniae are found to have a positive result of culture of blood for the organism [25] . Our study focused on bacteremic or other forms of invasive pneumococcal pneumonia that required hospitalization to permit analysis of outcomes adjusted for sus- ceptibility of the infecting organism. Although this sample is a subset of the full spectrum of pneumonia caused by S. pneumoniae, it is one in which any impact of resistance on clinical outcomes would likely be greatest. We found that drug resistance did not measurably affect mortality or admission to an ICU for hospitalized patients with invasive pneumococcal pneumonia. In contrast, severity of illness at presentation, advanced age, and underlying disease do appear to influence these outcomes. Our ability to detect an effect may have been hampered by the presence of few patients with isolates fully resistant to cefotaxime (MIC, у2.0 mg/mL; 38 patients) and relatively small numbers of persons who received therapy classified as discordant (22 patients [15%] ). Because we focused on invasive disease and pneumonia that required hospitalization, aggressive empirical antibiotic therapy was common, which reduced the likelihood that a patient would receive a drug to which the pathogen was resistant.
Very few instances of discordant therapy were observed because patients often received regimens that consisted of у2 different classes of antibiotics in the first 48 h of treatment. Among 45 case patients who were infected with a pneumococcal strain that was fully resistant to cefotaxime, 14 (31%) received an antibiotic to which the infection was fully susceptible. However, even among the 20 of these case patients to whom discordant therapy was given, patients did not appear to have consequences measurable by the end points that were analyzed. Whereas deaths and ICU admissions did not occur at a higher rate among those who received discordant therapy, the small 
